Alvotech (HAM:Z45) Tariff Resilience Score: 6/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Z45 Alvotech HAM:Z45
48 GF Score
Price €2.95
GF Value €16.65
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Alvotech Tariff Resilience Score?

Alvotech HAM:Z45 +8.06% 48 Tariff Resilience Score is 6 as of Jul. 15, 2026. GuruFocus rates HAM:Z45 with a GF Score™ of 48/100 and a GF Value™ of €16.65 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Alvotech ranks better than 91.06% on this metric.

Alvotech has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Alvotech has Alvotech's global supply chain for biosimilars is moderately exposed to tariffs. Manufacturing in Iceland with sales in the US and EU, it faces some risk. However, its focus on biosimilars, which are less tariff-sensitive, and potential for alternative suppliers provide some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Alvotech might have Average Resilient.

Alvotech  (HAM:Z45) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Alvotech Tariff Resilience Score Related Terms

HAM:Z45 vs PAHC, COLL, XERS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Alvotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alvotech Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alvotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Alvotech's Tariff Resilience Score falls into.


HAM:Z45
48GF Score
Alvotech HAM:Z45
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Alvotech (HAM:Z45) has a Tariff Resilience Score of 6 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Alvotech ranks #92 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Alvotech's Tariff Resilience Score too high?
Alvotech's current Tariff Resilience Score is 6. Based on the distribution chart, Alvotech ranks #92 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alvotech has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Tariff Resilience Score compare to PAHC and COLL?
According to the Drug Manufacturers industry distribution chart, Alvotech ranks #92 out of 1029 companies for Tariff Resilience Score. This places Alvotech in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Alvotech's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (HAM:Z45) is currently considered Possible Value Trap. The stock's GF Value™ is €16.65, compared to a current price of €2.95 — trading 82.3% below its estimated fair value. The current Tariff Resilience Score is 6. Alvotech's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Alvotech (HAM:Z45), the current Tariff Resilience Score is 6 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (HAM:Z45) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of €2.95 is trading 82.3% below its estimated GF Value™ of €16.65. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for HAM:Z45:

  • Tariff Resilience Score: 6
  • GF Value™: €16.65 vs. price of €2.95 (82.3% below fair value)
  • GF Score™: 48/100 with 7 warning signs

No single metric tells the full story. See the HAM:Z45 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alvotech Business Description

Other Exchanges ALVO:USAALVO:Iceland
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
48GF Score

Get the complete analysis for HAM:Z45

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.95
Price
€16.65
GF Value